N1BI34 Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$31.09 |
| 52 Week High | US$44.95 |
| 52 Week Low | US$30.55 |
| Beta | 0.35 |
| 1 Month Change | -8.56% |
| 3 Month Change | -24.76% |
| 1 Year Change | -15.33% |
| 3 Year Change | 34.01% |
| 5 Year Change | n/a |
| Change since IPO | 9.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| N1BI34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -2.6% | -0.9% | 2.4% |
| 1Y | -15.3% | -3.4% | -3.2% |
Return vs Industry: N1BI34 underperformed the BR Biotechs industry which returned -3.4% over the past year.
Return vs Market: N1BI34 underperformed the BR Market which returned -3.2% over the past year.
Price Volatility
| N1BI34 volatility | |
|---|---|
| N1BI34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 2.8% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine N1BI34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,800 | Kyle Gano | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
Neurocrine Biosciences, Inc. Fundamentals Summary
| N1BI34 fundamental statistics | |
|---|---|
| Market cap | R$63.77b |
| Earnings (TTM) | R$1.95b |
| Revenue (TTM) | R$13.46b |
32.7x
P/E Ratio4.7x
P/S RatioIs N1BI34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N1BI34 income statement (TTM) | |
|---|---|
| Revenue | US$2.36b |
| Cost of Revenue | US$765.10m |
| Gross Profit | US$1.59b |
| Other Expenses | US$1.25b |
| Earnings | US$341.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.42 |
| Gross Margin | 67.52% |
| Net Profit Margin | 14.49% |
| Debt/Equity Ratio | 0% |
How did N1BI34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 21:21 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |